“We have a positive trial,” announced Laura Baker of Wake Forest University, North Carolina, drawing cheers during her plenary at the 2025 Alzheimer’s Association International Conference (AAIC) in ...

The investigational drug obicetrapib blocks the transfer of cholesteryl esters from high- to low-density lipoprotein. In a cardiovascular disease trial, it reduced plasma p-tau217.

AAV-sTREM2 5xFAD mice were created to study the long-term effects of soluble TREM2 (sTREM2) in the context of amyloidosis. To generate this model, AAV carrying cDNA encoding EGFP- and FLAG-tagged ...

In a Phase 2 trial, donanemab completely cleared plaque in two-thirds of participants. Their cognitive decline slowed by a third, meeting the primary endpoint. The treatment appeared to nudge down ...

Scientists from academia, pharmaceutical companies, and healthcare analysis firms reached no consensus on a threshold for meaningfulness, but broadly agreed that meaningfulness should be determined ...

Lecanemab binds protofibrils more tightly than fibrils, perhaps explaining lower ARIA rate. Use of plasma biomarkers brings down trial screening cost. Lecanemab has been selected for the first amyloid ...

Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

Blood-brain barrier model combines human astrocytes, pericytes, and endothelial cells. APOE4 in pericytes, but not the other cells, promoted cerebral amyloid angiopathy. Blocking NFAT signaling ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

Sasner sat down with Alzforum to go over what models are available now, which ones are coming, and how they could be used. The new mouse lines are the product of two different initiatives: NIA’s Model ...

First genome-wide CRISPR screens in human neurons tweaks gene expression. Endolyosomal function, oxidative stress, and iron homeostasis genes key to neuronal survival. Sans lysosomal prosaposin, ...